Neuren Pharmaceuticals Limited
NURPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,599 | $3,167 | $1,007 | $452 |
| - Cash | $3 | $17 | $40 | $37 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1,596 | $3,149 | $967 | $415 |
| Revenue | $217 | $232 | $15 | $3 |
| % Growth | -6.5% | 1,493.7% | 355.2% | – |
| Gross Profit | $184 | $205 | $15 | $3 |
| % Margin | 84.8% | 88.5% | 99.9% | 99.7% |
| EBITDA | $179 | $199 | -$1 | -$8 |
| % Margin | 82.6% | 85.9% | -5% | -257.3% |
| Net Income | $142 | $157 | $0 | -$8 |
| % Margin | 65.5% | 67.7% | 1.3% | -243.8% |
| EPS Diluted | 1.09 | 1.2 | 0.001 | -0.066 |
| % Growth | -9.2% | 85,614.3% | 102.1% | – |
| Operating Cash Flow | -$11 | $185 | $4 | -$10 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$11 | $185 | $4 | -$10 |